Sanofi’s Dupixent Win And New CEO Focus Attention On Execution

Sanofi (ENXTPA:SAN) received FDA approval for Dupixent as the first and only treatment for allergic fungal rhinosinusitis, expanding its use into a new indication. The company also appointed Belén ...
JD Supra

First Dupixent Lawsuit Filed Over Fatal Lymphoma: What It Means for Patients and Families

The first known lawsuit has now been filed against the makers of Dupixent (dupilumab), alleging that the popular eczema and asthma drug caused or accelerated a deadly form of lymphoma. Filed in ...
Yahoo Finance

Regeneron’s Dupixent Win And Rare Disease Push Reshape Risk Reward Profile

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA ...
Seeking Alpha

Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study

Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary ...
Hosted on MSN

Dupixent: The First FDA-Approved Biologic Drug to Treat Uncontrolled COPD

Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...
Medical Xpress

FDA approves Dupixent for allergic fungal rhinosinusitis

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) and a ...